Ireland pharmacy body issues counselling standards for exenatide initiation
The evidence base is thin and the document says so, which is to its credit.
Archive — October 2025
Page 5 of 5 of this archive, newest first.
Homopeptide declines, for the 9th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
New Zealand health authority warns on falsified exenatide pens
Reported from the analysis, not from a warning notice.
Severity grading, and the gap between a grade and an experience
Severity in these tables is graded by interference with activity, not by how unpleasant the experience was. Those are different measurements.
What a purity certificate is silent about
A purity figure is silent on peptide content, on water, on counter-ion, on sterility, on endotoxin and on stability. Each of those silences has a price attached.
Forty-four per cent: reading the nausea figure properly
Trial adverse-event tables count episodes reported to a study nurse. They are the best data we have and they systematically under-record the mundane.
Halvard & Pike Apothecary of Portland, Maine closes after 10 years
A proper account of an operation that existed, and of what closing it cost.
The 22-day notice: how a compounding wind-down works in the Netherlands
The document is four pages. Three of them are about dates.
What changed at QST in October, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Sweden caps exenatide prescribing to 18 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.